<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Trimodality studies in pleural malignant pleural pneumonectomy</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Trimodality studies in pleural malignant pleural pneumonectomy</h1>
<div class="graphic"><div class="figure"><div class="ttl">Trimodality studies in pleural malignant pleural pneumonectomy</div><div class="cntnt"><table cellspacing="0"><colgroup span="9" width="11%"></colgroup> <tbody> <tr> <td class="subtitle1">Ref</td> <td class="subtitle1">n</td> <td class="subtitle1">Chemotherapy RR<br/> (percent)</td> <td class="subtitle1">EPP done<br/> (percent)</td> <td class="subtitle1">Mortality<br/> (percent)</td> <td class="subtitle1">Completed trimodal<br/> (percent)</td> <td class="subtitle1">OS (ITT) months</td> <td class="subtitle1">OS: Subsets months</td> <td class="subtitle1">PFS months</td> </tr> <tr> <td><strong>Weder<sup>[1]</sup></strong></td> <td class="centered">19</td> <td class="centered">32</td> <td class="centered">84</td> <td class="centered">0</td> <td class="centered">68</td> <td class="centered">23</td> <td class="centered">NR</td> <td class="centered">CT + EPP: 16.5</td> </tr> <tr> <td><strong>Weder<sup>[2]</sup></strong></td> <td class="centered">61</td> <td class="centered">NR</td> <td class="centered">74</td> <td class="centered">2.2</td> <td class="centered">59</td> <td class="centered">19.8</td> <td class="centered">CT + EPP: 23</td> <td class="centered">CT + EPP: 13.5</td> </tr> <tr> <td><strong>Rea<sup>[3]</sup></strong></td> <td class="centered">21</td> <td class="centered">33</td> <td class="centered">81</td> <td class="centered">0</td> <td class="centered">71</td> <td class="centered">25.5</td> <td class="centered">27.5</td> <td class="centered">CT + EPP: 16.3</td> </tr> <tr> <td><strong>Flores<sup>[4]</sup></strong></td> <td class="centered">21</td> <td class="centered">26</td> <td class="centered">42</td> <td class="centered">0</td> <td class="centered">42</td> <td class="centered">19</td> <td class="centered">CT + EPP + RT: 33.5</td> <td class="centered">NR</td> </tr> <tr> <td><strong>Opitz<sup>[5]</sup></strong></td> <td class="centered">63</td> <td class="centered">32</td> <td class="centered">–</td> <td class="centered">3.2</td> <td class="centered">–</td> <td class="centered">NR</td> <td class="centered">NR</td> <td class="centered">NR</td> </tr> <tr> <td><strong>Buduhan<sup>[6]</sup></strong></td> <td class="centered">55</td> <td class="centered">NR</td> <td class="centered">84</td> <td class="centered">4.3</td> <td class="centered">69</td> <td class="centered">NR</td> <td class="centered">CT + EPP: 24<br/> TMT: 25</td> <td class="centered">NR</td> </tr> <tr> <td><strong>de Perrot<sup>[7]</sup></strong></td> <td class="centered">60</td> <td class="centered">NR</td> <td class="centered">75</td> <td class="centered">6.7</td> <td class="centered">50</td> <td class="centered">14</td> <td class="centered">NR</td> <td class="centered">NR</td> </tr> <tr> <td><strong>Krug<sup>[8]</sup></strong></td> <td class="centered">77</td> <td class="centered">32</td> <td class="centered">70</td> <td class="centered">4</td> <td class="centered">52</td> <td class="centered">16.8</td> <td class="centered">CT + EPP: 21.9<br/> TMT: 29.1</td> <td class="centered">ITT: 10.1<br/> CT + EPP: 18.3</td> </tr> <tr> <td><strong>Van Schil<sup>[9]</sup></strong></td> <td class="centered">58</td> <td class="centered">43</td> <td class="centered">72</td> <td class="centered">6.5</td> <td class="centered">65</td> <td class="centered">18.4</td> <td class="centered">TMT: 33</td> <td class="centered">ITT: 13.9</td> </tr> <tr> <td><strong>Rea<sup>[10]</sup></strong></td> <td class="centered">54</td> <td class="centered">29</td> <td class="centered">83</td> <td class="centered">NR</td> <td class="centered">41</td> <td class="centered">15.5</td> <td class="centered">NR</td> <td class="centered">ITT PFS: 8.6</td> </tr> <tr> <td><strong>Bille<sup>[11]</sup></strong></td> <td class="centered">25</td> <td class="centered">NR</td> <td class="centered">88</td> <td class="centered">4</td> <td class="centered">71</td> <td class="centered">12.8</td> <td class="centered">NR</td> <td class="centered">NR</td> </tr> <tr> <td><strong>Okada<sup>[12]</sup></strong></td> <td class="centered">27</td> <td class="centered">NR</td> <td class="centered">100</td> <td class="centered">3.7</td> <td class="centered">63</td> <td class="centered">13</td> <td class="centered">23 (chemoRT after EPP)</td> <td class="centered">NR</td> </tr> </tbody></table></div><div class="graphic_footnotes">RR: response rate; EPP: extrapleural pneumonectomy; OS: overall survival; PFS: progression free survival; CT: chemotherapy; TMT: trimodality therapy; ITT: intent to treat; NR: not recorded.</div><div class="graphic_reference">References:<br/><ol>
<li>Weder W, et al. Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. J Clin Oncol 22(17):3451, 2004.</li>
<li>Weder W, et al. Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Ann Oncol 18(7):1196, 2007.</li>
<li>Rea F, et al. Induction chemotherapy, extrapleural pneumonectomy (EPP) and adjuvant hemi-thoracic radiation in malignant pleural mesothelioma (MPM): Feasibility and results. Lung Cancer 57(1):89, 2007.</li>
<li>Flores RM, et al. Induction chemotherapy, extrapleural pneumonectomy, and postoperative high-dose radiotherapy for locally advanced malignant pleural mesothelioma: a phase II trial. J Thorac Oncol 1(4):289, 2006.</li>
<li>Opitz I, et al. Incidence and management of complications after neoadjuvant chemotherapy followed by extrapleural pneumonectomy for malignant pleural mesothelioma. Eur J Cardiothorac Surg 29(4):579, 2006.</li>
<li>Buduhan G, et al. Trimodality therapy for malignant pleural mesothelioma. Ann Thorac Surg 88(3):870, 2009.</li>
<li>de Perrot M, et al. Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Clin Oncol 27(9):1413, 2009.</li>
<li>Krug LM, et al. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol 27(18):3007, 2009.</li>
<li>Van Schil PE, et al. Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial. Eur Respir J 36(6):1362, 2010.</li>
<li>Pasello G, et al. Pemetrexed plus carboplatin or cisplatin as neoadjuvant treatment of operable malignant pleural mesothelioma (MPM). Anticancer Res 32(12):5393, 2012.</li>
<li>Bille A, et al: Induction chemotherapy, extrapleural pneumonectomy, and adjuvant radiotherapy for malignant pleural mesothelioma: experience of Guy's and St Thomas' hospitals. Gen Thorac Cardiovasc Surg 60(5):289, 2012.</li>
<li>Okada K: Trimodality Therapy With Extrapleural Pneumonectomy, Radiation Therapy, And Chemotherapy For Malignant Pleural Mesothelioma. 11th International Conference of the International Mesothelioma Interest Group. 2012.</li></ol></div><div id="graphicVersion">Graphic 88466 Version 3.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
